EA201490220A1 - Композиция и способ лечения hpv - Google Patents

Композиция и способ лечения hpv

Info

Publication number
EA201490220A1
EA201490220A1 EA201490220A EA201490220A EA201490220A1 EA 201490220 A1 EA201490220 A1 EA 201490220A1 EA 201490220 A EA201490220 A EA 201490220A EA 201490220 A EA201490220 A EA 201490220A EA 201490220 A1 EA201490220 A1 EA 201490220A1
Authority
EA
Eurasian Patent Office
Prior art keywords
relates
compositions
hpv
composition
treatment
Prior art date
Application number
EA201490220A
Other languages
English (en)
Inventor
Мари Пьетте
Бриджитт Эврар
Изабэль Коия
Original Assignee
Фемалон С.П.Р.Л.
Юниверситэ Дэ Либр Дэ Брюксель
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45877205&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490220(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фемалон С.П.Р.Л., Юниверситэ Дэ Либр Дэ Брюксель filed Critical Фемалон С.П.Р.Л.
Publication of EA201490220A1 publication Critical patent/EA201490220A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к лиофилизированным композициям, включающим цидофовир, гидроксипропилметилцеллюлозу (НРМС) или гидроксиэтилцеллюлозу (НЕС) и необязательно пластификатор. В частности, изобретение относится к композициям, которые образуют листообразную пористую твердую матрицу. Изобретение также относится к способам получения данных композиций. Изобретение также относится к композициям для применения при лечении инфекций, вызванных папилломавирусом человека (HPV) и связанных с HPV злокачественных опухолей, в частности HPV поражений и цервикального рака.
EA201490220A 2011-07-15 2012-07-13 Композиция и способ лечения hpv EA201490220A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161508473P 2011-07-15 2011-07-15
EP11174193 2011-07-15
PCT/EP2012/063796 WO2013010942A1 (en) 2011-07-15 2012-07-13 Composition and method for treating hpv

Publications (1)

Publication Number Publication Date
EA201490220A1 true EA201490220A1 (ru) 2014-07-30

Family

ID=45877205

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490220A EA201490220A1 (ru) 2011-07-15 2012-07-13 Композиция и способ лечения hpv

Country Status (12)

Country Link
US (1) US9211338B2 (ru)
EP (1) EP2731588B1 (ru)
JP (1) JP2014520834A (ru)
KR (1) KR20140054067A (ru)
CN (1) CN103889400A (ru)
AU (1) AU2012285969A1 (ru)
BR (1) BR112014000877A2 (ru)
CA (1) CA2841851A1 (ru)
CL (1) CL2014000110A1 (ru)
EA (1) EA201490220A1 (ru)
MX (1) MX2014000522A (ru)
WO (1) WO2013010942A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841851A1 (en) 2011-07-15 2013-01-24 Femalon S.P.R.L. Composition and method for treating hpv
US20200253994A1 (en) * 2019-02-11 2020-08-13 Chemistryrx Pyrimidine derivative containing compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
CN1698643A (zh) * 2005-05-27 2005-11-23 山东恒瑞医药科技发展有限公司 西多福韦脂质体及其制备方法
WO2007035515A2 (en) * 2005-09-15 2007-03-29 Umd, Inc. A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration
EP1837020A1 (en) 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
CA2841851A1 (en) 2011-07-15 2013-01-24 Femalon S.P.R.L. Composition and method for treating hpv

Also Published As

Publication number Publication date
CN103889400A (zh) 2014-06-25
CA2841851A1 (en) 2013-01-24
EP2731588A1 (en) 2014-05-21
WO2013010942A1 (en) 2013-01-24
KR20140054067A (ko) 2014-05-08
AU2012285969A1 (en) 2014-01-30
JP2014520834A (ja) 2014-08-25
CL2014000110A1 (es) 2014-10-24
US20140170219A1 (en) 2014-06-19
US9211338B2 (en) 2015-12-15
NZ620042A (en) 2015-09-25
MX2014000522A (es) 2014-05-30
BR112014000877A2 (pt) 2017-02-21
EP2731588B1 (en) 2016-04-06

Similar Documents

Publication Publication Date Title
CY1123739T1 (el) Αντισωματα anti-cd38
WO2019229701A3 (en) Binding molecules against bcma and uses thereof
EP3584251A3 (en) Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
RS20140202A1 (en) BIOSPECIFIC IMMUNOVELING PROTEINS DIRECTED AGAINST TNF AND IL-17
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
MX2011011505A (es) Vacuna neumococica y usos de la misma.
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
TN2012000414A1 (en) Forms of rifaximin and uses thereof
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
TR201908199T4 (tr) HPV'ye karşı aşılar.
UA113956C2 (xx) Похідні піримідину для лікування вірусних інфекцій
EP4230641A3 (en) Human cd30 ligand antigen binding proteins
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
BR112013030150A2 (pt) proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
CY1118704T1 (el) Ανθρωπινος πληθυσμος βλαστοκυτταρων του τραχηλου της μητρας και χρησεις αυτου
WO2017192418A8 (en) Therapeutic hpv vaccine combinations
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
EA201490220A1 (ru) Композиция и способ лечения hpv
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
MX360449B (es) Vacunas para el virus del papiloma humano y metodos para su uso.